Annual report [Section 13 and 15(d), not S-K Item 405]

Cover

v3.25.1
Cover - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2024
Apr. 15, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 001-38022    
Entity Registrant Name MATINAS BIOPHARMA HOLDINGS, INC.    
Entity Central Index Key 0001582554    
Entity Tax Identification Number 46-3011414    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 1545 Route 206 South    
Entity Address, Address Line Two Suite 302    
Entity Address, City or Town Bedminster    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07921    
City Area Code 908    
Local Phone Number 484-8805    
Title of 12(b) Security Common Stock, par value $0.0001    
Trading Symbol MTNB    
Security Exchange Name NYSEAMER    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 38.7
Entity Common Stock, Shares Outstanding   5,086,985  
Documents Incorporated by Reference [Text Block] None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.0001    
Auditor Firm ID 274    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of Matinas BioPharma Holdings, Inc and Subsidiaries as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the position of the Company as of December 31, 2024 and 2023, and the results of their operations and their cash flows for each of the years in then ended in conformity with accounting principles generally accepted in the United States of America    
Auditor Name EISNERAMPER LLP    
Auditor Location Iselin, New Jersey